Treatment of Asthma (difficulty in breathing) by Unani medicine Laooq-e- Zeequn Nafas

Phase 3

Not yet recruiting

• Conditions: Mild intermittent asthma,

• Registration Number: CTRI/2020/02/023639
• Lead Sponsor: Central Council for Research in Unani Medicine CCRUM New Delhi

Brief Summary

This study is designed as a multicentric open trial in patients with **Zeequn Nafas (Bronchial Asthma)****.** After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria. The patients will be treated with Unani pharmacopoeial formulation **Laooq-e- Zeequn Nafas 5gm twice** daily with lukewarm water for four weeks.  The patients will be assessed at every week. This includes subjective assessment of general well being and physical examination . The total duration of treatment will be four weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

**Composition of *Laooq-e- Zeequn Nafas***

| | | | |

| --- | --- | --- | --- |

|**S. No.**

**Ingredients**

**Botanical / Chemical Name**

**Quantity**

|

Tukhm-e-Katan

*Linum usitatissimum* (Seed)

60 gm.

|

Maghz Badam Shireen Muqashshar

*Prunus amygdalus* (Dehusk Kernel)

60 gm.

|

Maweez Munaqqa

*Vitis vinifera*

30 gm.

|

Kateera

*Cochlospermum religiosum* (Gum)

30 gm.

|

Asl-us-Soos

*Glycyrrhiza glabra*

30 gm.

|

Maghz-e-Chilghoza

*Pinus gerardiana* (Kernel)

30 gm.

|

Nishasta-e-Gandum

*Triticum* *aestivum*

30 gm.

|

Samagh-e-Arabi

*Acacia arabica* (Gum)

30 gm.

|

Tukhm-e-Hulba

*T**rigonella foenum-graecum* (Seed)

10 gm

|

Qand Safaid

Sugar

600 gm

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2020-02-17
• Study Start: 2020-02-28

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• 1.Males and females of 18-65 years.
• 2.Patients of Bronchial Asthma for at least 6 months presenting with at least one of the following symptoms: a.Wheeze b.Shortness of breath c.Chest tightness and cough that vary over time and in intensity, d.Expiratory airflow limitation as suggested by a decreased FEV1 3.Objective evidence for reversible airway obstruction (≥12% and ≥200 mL change in FEV1 and/or a 25% and 60 L/min change in PEFR) either spontaneously or after treatment.
• 4.Patients with Asthma Control Questionnaire Score > 1.5.

Exclusion Criteria

• 1.FEV1/FVC ratio < 50% 2.Pregnant and lactating mother 3.Patient with other Respiratory Tract Infections, tuberculosis and malignancy.
• 4.Patient of Presence of chronic cough with expectoration for 2-3 months in each of 2 successive years.
• 5.Patient with co-morbidities, Diabetes Mellitus, Hepatic and Renal Insufficiency.
• 6.Patients with Tobacco Smoking.
• 7.Patient with regular use of oral or systemic corticosteroids for conditions other than Asthma.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in signs and symptoms of Zeequn Nafas (Bronchial Asthma)	4 weeks

Secondary Outcome Measures

Name	Time	Method
Haematological and biochemical assessment for safety assessment	Investigations will be done at baseline and end of treatment

Trial Locations

Locations (2)

Central Research Institute of Unani Medicine (CRIUM)); 🇮🇳 Hyderabad, TELANGANA, India

Regional Research Institute of Unani Medicine (RRIUM); 🇮🇳 Bhadrak, ORISSA, India

Central Research Institute of Unani Medicine (CRIUM))

🇮🇳Hyderabad, TELANGANA, India

Dr Anwar Ahmed

Principal investigator

9440417005

dranwar_ahmed@yahoo.com